About PharmaDerm
PharmaDerm is a specialty pharmaceutical company dedicated to developing and commercializing prescription products to treat diseases and conditions of the skin—the largest organ of the human body. Our goal is to pursue development of products that will help improve the lives of patients with skin disease.
Our growing portfolio of products provide effective prescription therapies for the treatment of a variety of skin diseases including acne, actinic keratosis (AK), eczema, external genital warts, fungal disease, psoriasis and rosacea.
PharmaDerm, combined with our sister generic division, Fougera, is the number one manufacturer of topical pharmaceutical products in the United States. Over the last 8 years, we have developed over 60 FDA-approved topical therapies in the United States—more than any other company in that time frame.
PharmaDerm is uniquely positioned as a fully vertically-integrated specialty pharmaceutical company dedicated to skin disease with in-house expertise and facilities for formulation development, clinical development, manufacturing, distribution, sales and marketing.
Important Product Safety Information
VEREGEN® Ointment, 15% is a medicine for skin use only (topical) for the treatment of warts on the outside of the genitals and around the outside of the anus. It is not a treatment for warts in the vagina, cervix, or inside the anus. Your doctor may recommend examination and screening tests (such as a Pap smear) to evaluate these areas.
VEREGEN® has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds. Do not expose skin that has been treated with VEREGEN® to the sun or ultraviolet light because VEREGEN® has not been tested in these conditions. Safety and efficacy of VEREGEN® have not been established in immunosuppressed or pediatric patients, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.
The most common adverse reactions that occurred in more than 20% of patients in studies with VEREGEN® were reactions of the skin and application site. These included reddening of the skin, itching, burning, pain or discomfort, skin ulcers, wearing down of the skin, swelling, hard spots, and rash with blisters.
VEREGEN® (sinecatechins) Ointment Full Prescribing Information
